Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
GlobalData on MSN2d
Gilead and MSD to advance once-weekly HIV treatment to Phase IIIThe companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...
Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
News Medical on MSN2d
Affordability and supply remain critical to the success of long-lasting HIV drugAffordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Winnie Byanyima, from UNAIDS: ‘Lenacapavir is more effective than condoms or PrEP in prevention’
The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
Leerink has upgraded Gilead Sciences (NASDAQ:GILD) to outperform, citing the growth outlook for its PrEP treatment lenacapavir ... longer-acting HIV drugs “has an outsize impact on GILD ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
An analysis by Li Tao, MD, MS, PhD, director of real-world evidence at Gilead Sciences, and colleagues looked at statistical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback